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Abstract: This study examined the effect of yohimbine alone and in combination with glibenclamide on ischemia and reperfusioninduced arrhythmias in diabetes. Six minutes of ischemia were produced in 1-week diabetic rats by ligation of the left coronary artery,
and 6 min of reperfusion were produced by releasing the artery. A dose of 5 mg/kg of yohimbine and glibenclamide was administered
for 7 days prior to the coronary ligation. The blood pressure, heart rate, and arrhythmia were determined from the recorded ECG
during the 6 min of ischemia and reperfusion and then compared using a one-way ANOVA statistical program and the chi-square test.
The score of arrhythmia calculated from the type and duration of arrhythmia decreased in the diabetic rats (3.5 ± 1.69 in control, 1.7 ±
0.81 in diabetes group). The arrhythmia score returned to the control value in the rats that were given a combination of yohimbine and
glibenclamide (3 ± 1.73). Yohimbine is used in the treatment of erectile dysfunction; glibenclamide is used as an antidiabetic drug in
diabetic patients and may be a risk factor in the increase of ischemia reperfusion-induced arrhythmias.
Key words: Ischemia, reperfusion, arrhythmia, diabetes, glibenclamide, yohimbine

1. Introduction
Ischemia that occurs following the occlusion of coronaries
and reperfusion by reopening of the vessel induces
lethal arrhythmia that is observed both in humans and
experimentally in animals. In various studies (Balakumar
et al., 2012; Nakau et al., 2012) it has been found that
arrhythmias observed following myocardial ischemia
and reperfusion decrease in the early stages of diabetes,
whereas they increase in the later stages. However, the
reason for this different response in diabetic rats is still
a subject of ongoing research. Diabetic patients are
susceptible to various diseases as well as to the effect of
yohimbine and glibenclamide, which might be candidate
drugs for the treatment of those diseases. Although the
antiarrhythmic effect of yohimbine following ischemia and
reperfusion and the antidiabetic effect of glibenclamide
were shown experimentally in rats, their effects alone or in
combination in diabetic rats are not yet known. Yohimbine
decreases reperfusion-induced arrhythmias in nondiabetic
rats (Roegel et al., 1996; Bozdoğan et al., 2004; Bozdoğan
et al., 2013) and it has both an antidiabetic (Arrajab and
Ahren, 1991; Sandberg et al., 2013) and a cardiovascular
protective effect (Yiyang et al., 2013). Glibenclamide is
* Correspondence: bozdogan_o@ibu.edu.tr

commonly used as an antidiabetic drug, although its
effect on ischemia reperfusion-induced arrhythmia in
nondiabetic rats is controversial (El-Reyani et al., 1999;
Bozdoğan et al., 2000). Glibenclamide has been found
to increase ventricular tachycardia and fibrillation in
2-week diabetes (Tosaki et al., 1995). Glibenclamide and
yohimbine, which are used to treat diabetes and erectile
dysfunction, respectively, can be used in combination.
However, no studies have been conducted related to the
combined effect of yohimbine and glibenclamide on
ischemia reperfusion-induced arrhythmias in diabetes.
This research aimed to investigate the effects of yohimbine
alone and yohimbine in combination with glibenclamide
treatments on ischemia reperfusion-induced arrhythmias
in 1-week diabetic rats.
2. Materials and methods
2.1. Animals
In this study, 28 male rats between 6 and 7 months old
were used. Animals were raised in 12L/12D photoperiods
in a room with 40% humidity. Food and water were given
ad libitum. The rats were divided into 4 groups. The first
group was designated as the nondiabetic control; isotonic
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solution in the daily amount of 1 mL/kg was given
intraperitoneally to rats in this group during the 7 days
prior to operation. The second, third, and fourth groups
of rats were made diabetic via a single-dose injection of
50 mg/kg streptozotocin (STZ). Twenty-four hours after
the STZ application, 1 mL/kg isotonic solution, 5 mg/
kg yohimbine + 1 mL/kg isotonic solution, and 5 mg/kg
yohimbine and 5 mg/kg glibenclamide were given daily
to the second, third, and fourth groups, respectively, for
7 days. All injections were given intraperitoneally. At the
end of the 7 days animals in all groups were operated on
in order to produce myocardial ischemia and reperfusion.
2.2. Surgical procedures
The animals were anesthetized with 1.2 g/kg urethane prior
to the operation. A tracheotomy was then performed for
artificial respiration, and the carotid artery was cannulated
for blood pressure measurement. A thoracotomy from 4–5
intercostal spaces and a pericardiotomy were performed
to expose the heart. The heart was extracted from the
thorax by pressing it gently on either side. The left arteria
ramus interventricularis was ligated with 5/0 silk in
order to produce 6 min of ischemia, and then 6 min of
reperfusion was created by the releasing of this artery.
Artificial respiration during the operation was performed
at a rate of 60 strokes/min and 0.9 mL room air/100 mg
body weight. Animals that had blood pressure below 70
mmHg or arrhythmia before ligation were removed from
the studies.
2.3. Determination of risk of infarct zone
At the end of the experiments, the hearts were excised
out and the coronary artery was ligated again. The hearts
were perfused first with an isotonic solution and then with
ethanol for demarcation of the nonperfused area from
the perfused one. The nonperfused area remained light
pinkish in color, while the perfused one turned white in
color after the ethanol perfusion. The nonperfused area
was cut out and separated from the perfused one. The
weight of the nonperfused area was measured alone and
then together with the perfused area. The percentage of the
nonperfused area was calculated in respect to the whole
weight of the ventricle and designated as the risk of infarct
zone (Lepran et al., 1983).
2.4. Biochemical analysis
Blood glucose was measured by a glucometer (Glucotrend2,
Roche Group, UK) prior to the operation. Animals that
had a blood glucose level higher than 300 mg/dL were
accepted as diabetic (Pushparaj et al., 2007).
2.5. Recording
Electrocardiograms and the blood pressure were recorded
during ischemia and reperfusion using a computerized
recording system (Biopac System Inc., USA; Turkish
representative: Commat, Ankara, Turkey) using BSL Pro
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3.7 software. The duration and the type of arrhythmias
were determined from the recorded ECG according to the
Lambeth Convention (Curtis et al., 2013). An arrhythmia
score was defined in respect to the duration and type of
arrhythmia observed during the ischemia and reperfusion
in all animals where 0 indicates no arrhythmia, 1 indicates
an arrhythmia duration of less than 10 s (ventricular
tachycardia, extra systole, bigeminy or salvo), 2 indicates
an arrhythmia duration of 11–30 s, 3 indicates an
arrhythmia duration of 31–90 s, 4 indicates an arrhythmia
duration of 91–180 s or reversible ventricular fibrillation
(VF), 5 indicates an arrhythmia duration longer than
180 s or reversible VF for more than 10 s, and 6 indicates
irreversible VF or death of the animal (Yaşar et al., 2015).
The arrhythmia recorded during ischemia and reperfusion
in diabetic rats is shown in Figure 1.
2.6. Statistical analysis
All the mean values, including blood pressure, heart rate,
duration of arrhythmia, and the incidences of every type
of arrhythmia during the ischemia and reperfusion, were
analyzed and compared using one-way ANOVA. The
survival rate at the end of ischemia and reperfusion was
analyzed with the chi-square method (Fisher exact test).
3. Results
No statistically significant differences were found in the
heart rate and blood pressure before coronary ligation and
during ischemia among the groups (Table 1). The heart
rate during reperfusion in the diabetic rats decreased, but
the blood pressure did not change when compared to the
nondiabetic rats (Table 2).
The body weight measured at the end of 1 week
decreased in the diabetic groups in contrast to the
nondiabetic control (P < 0.05). Similarly, but not
significantly, the total ventricular weight decreased in the
diabetic rats (Table 3). The risk of the infarct zone after
the coronary ligation was found to be similar in all groups.
Blood glucose did not decrease in the diabetic rats after
the yohimbine application, both alone and in combination
with glibenclamide (Figure 2).
The total durations of the arrhythmias, the ventricular
arrhythmias, and the arrhythmia score determined during
the 6 min of ischemia were not found to be significantly
different in diabetic rats when compared with the
nondiabetic rats. The incidence of ventricular arrhythmia
and the survival rate determined at the end of the ischemia
were also similar among the groups. However, the
arrhythmia score calculated by examining the duration
and type of the arrhythmia recorded during reperfusion
was found to decrease significantly in the diabetic rats
both with and without the yohimbine treatment in respect
to the control (Table 4). The combination of glibenclamide
with yohimbine increased the arrhythmia score back to

Figure 1. Ventricular arrhythmias observed during ischemia and reperfusion. Record was taken from diabetic animals that were administered yohimbine and glibenclamide. VPC:
Ventricular premature contraction, VT: ventricular tachycardia, VF: ventricular fibrillation.
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Table 1. Heart rate and mean arterial blood pressure recorded before and during 6 min of ischemia.
Heart rate (beats/minute)
Groups

N

Control

8

Blood pressure (mmHg)

Following ligation

Before
ligation

1 min

3 min

358 ± 20

348 ± 28

347 ± 28

Following ligation

5 min

Before
ligation

1 min

3 min

5 min

339 ± 35

111 ± 5

80 ± 9

83 ± 10

78 ± 10

STZ

6

317 ± 14

341.9 ± 24.18

314 ± 21

308 ± 23

114 ± 6

83 ± 11

92 ± 7

86 ± 6

STZ + YH

7

358 ± 16

351.6 ± 13.35

358 ± 12

347 ± 14

115 ± 2

83 ± 6

89 ± 9

90 ± 6

STZ + YH + GL

7

337 ± 22

364.9 ± 41.56

340 ± 25

328 ± 27

113 ± 5

84 ± 8

89 ± 6

78 ± 4

Control: Nondiabetic rats, STZ: diabetic rats, STZ + YH: diabetic rats treated with yohimbine, STZ + YH + GL: diabetic rats treated
with combination of yohimbine and glibenclamide. N: Number of surviving animals at the end of 6 min of ischemia. Values represent
mean ± standard error.
Table 2. Heart rate and mean arterial blood pressure recorded during 6 min of reperfusion.

Groups

N

Control
STZ

Heart rate ( beats/minute)

Arterial blood pressure (mmHg)

1 min

3 min

5 min

1 min

3 min

5 min

8

453 ± 88

379 ± 23,

381 ± 22

58 ± 5

72 ± 12

67 ± 11

6

304 ± 18*

303 ± 23*

300 ± 23*

76 ± 10

85 ± 11

83 ± 10

STZ + YH

7

355 ± 13

351 ± 8

343 ± 15

89 ± 7

77 ± 8

89 ± 9

STZ + YH + GL

7

324 ± 25*

319 ± 29

324 ± 30

85 ± 11

99 ± 9

90 ± 9

N: Number of surviving animals at the end of 6 min of reperfusion. Values represent mean ± standard error. *P < 0.05; different from
control.
Table 3. Weight of body and ventricle at the end of reperfusion and risk of infarct zone.
Body weight (g)
Before STZ

After STZ

Ventricle
weight (g)

Risk of infarct
zone (%)

8

391 ± 11

388 ± 8

1.15 ± 0.09

47.4 ± 2.25

6

344 ± 14

325 ± 18*

0.85 ± 0.06*

48.3 ± 3.57

STZ + YH

7

325 ± 21

275 ± 22*

0.75 ± 0.04*

47.2 ± 1.83

ST + YH + GL

7

374 ± 8

325 ± 10*

0.91 ± 0.06*

50.8 ± 1.11

Groups

N

Control
STZ

N: Number of surviving animals at the end of 6 min of reperfusion. Values represent mean ± standard
error. *P < 0.05; different from control.

the control level. The incidence of ventricular tachycardia
and VF during reperfusion decreased in the diabetic
rats in respect to the control rats (Table 4) at P < 0.05.
The decrease in the incidence of ventricular tachycardia
and VF was also seen in the yohimbine-treated diabetic
rats. However, the combination of glibenclamide with
yohimbine nonsignificantly increased the incidences of
these arrhythmias back to control levels (Table 4). The
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arrhythmia started earlier during reperfusion in the
diabetic rats in contrast to the control animals (Table 5)
at P < 0.05. On the other hand, the arrhythmic period
during reperfusion measured between the start and the
end of arrhythmia increased in all the diabetic groups
compared to the nondiabetic control (Table 5) at P < 0.05.
Bradycardia was observed in the control groups, but not in
the diabetic rats.

Glucose level (mg /dL)
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500
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Control

STZ

STZ + YH

STZ + YH + GL

Figure 2. Blood glucose levels. Control: Nondiabetic rats, STZ:
diabetic rats, STZ + YH: diabetic rats treated with yohimbine,
STZ + YH + GL: diabetic rats treated with combination of
yohimbine and glibenclamide. *P < 0.05; different from control.

4. Discussion
Previous studies (Tosaki et al., 1995; Zhang et al.,
2002; Ravingerova et al., 2003) have shown that shortterm diabetic duration decreases reperfusion-induced
ventricular arrhythmias. This is consistent with the
results of the present study. Yohimbine did not change

the incidences of these arrhythmias. The combination
of glibenclamide and yohimbine increasing ventricular
arrhythmias in diabetic rats compared to a nondiabetic
control is being reported in this study for the first time.
However, in a similar study, opposite results were reported
(Tosaki et al., 1995). This difference may be due to two
reasons: the effect of glibenclamide was examined in
the later stage of diabetes, and a global ischemia and
reperfusion model was performed in that study. The
effect of yohimbine on ischemia and reperfusion-induced
arrhythmia in the diabetic rats was first examined in this
study. Yohimbine did not change the cardioprotection
induced by the diabetes against arrhythmia. Several
studies have shown that yohimbine decreases ischemia and
reperfusion-induced arrhythmia in normal rats (Francis
et al., 1983; Bozdoğan et al., 2004; Yiyang et al., 2013). In
contrast to the protection against ischemia reperfusion
arrhythmia generated in the early phase of diabetes, this
protection disappeared in the late phase of diabetes, as
has been previously shown (Balakamur et al., 2012). The
protective effect of diabetes against ischemia reperfusioninduced arrhythmia was observed as variable, as it was
examined in the early and late stages of diabetes (Goel and

Table 4. The incidence of arrhythmia and arrhythmia score determined at the end of 6 min of reperfusion.

Groups

N

Survival
rate (%)

Incidence (N/%)
VF

VT

Others

Bradycardia

Arrhythmia
score

Control

8

100

4 / 50

6 / 75

8 / 100

4 / 50

3.5 ± 1.69

STZ

6

100

0 / 0*

1 / 16*

6 / 100

0 / 0*

1.7 ± 0.81*

STZ + YH

7

100

1 / 14

1 / 14*

5 / 71

0 / 0*

1.6 ± 1.39*

STZ + YH + GL

7

100

2 / 28

5 / 71

6 / 85

0 / 0*

3 ± 1.73

N: Number of surviving animals at the end of 6 min of reperfusion. Values represent mean ± standard error. *P < 0.05; different
from control. VF: Ventricular fibrillation, VT: ventricular tachycardia. Others: Ventricular extrasystole, bigeminal ventricular
arrhythmia, salvo. N/%: Number of animals/percentage.

Table 5. Duration of arrhythmia determined during 6 min of reperfusion.

Groups

N

Start of
Arrhythmic
arrhythmia (s) period (s)

Duration of arrhythmia (s)

Control

8

85.1 ± 41.81

144.8 ± 31.78

STZ

6

40.2 ± 14.95*

196.3 ± 47.25*

STZ + YH

7

21.4 ± 11.08*

STZ + YH + GL

7

7.7 ± 7.05*

VF

VT

Others

Total

Bradycardia

49.4 ± 33.75 7.7 ± 2.67

17.9 ± 4.70

75.0 ± 34.79

68.3 ± 40.60

0.0

0.8 ± 0.81

15.5 ± 5.30

13.4 ± 5.45

0.0*

69.0 ± 38.65

1.3 ± 1.28

10.7 ± 10.68

15.3 ± 5.30

40.7 ± 15.39

0.0*

118.0 ± 47.49

6.5 ± 4.28

15.1 ± 6.57

13.5 ± 3.53

21.0 ± 7.95

0.0*

N: Number of surviving animals at the end of 6 min of reperfusion. Values represent mean ± standard error. *P < 0.05; different from
control.
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Pierce, 1999; Akula et al., 2003; Ravingerova et al., 2003).
The underlying mechanism of this protection is not the
focus and lies outside the scope of this research. However,
it is clearly demonstrated that a 1-week diabetic duration
results in the decrease of ischemia and reperfusion-induced
arrhythmia. Myocardial injury following coronary ligation
was shown to decrease in the initial stage, but it increased
in the later one (Akula et al., 2003; Nakou et al., 2012). A
period of 6 weeks of hyperglycemia was mentioned as the
reason for increased myocardial injury (Akula et al., 2003).
In another study it was shown that diabetes increases the
sensitivity of the myocardium to ischemia and reperfusion
injury, and also increases the infarct size while decreasing
the superoxide dismutase activity in the early stage (Haobo
et al., 2013).
Sulfonylurea drugs are commonly used to treat diabetes.
However, these drugs also increase erectile dysfunction
(Freitas et al., 2009). No epidemic research was found on
whether the incidence of erectile dysfunction increases in
patients using glibenclamide. In an experimental study
it was shown that glibenclamide decreases arrhythmia
following ischemia reperfusion in diabetes (Tosaki
et al., 1995). There are various studies indicating that
glibenclamide either decreases or increases the ischemia
reperfusion-induced arrhythmia in nondiabetic rats (ElReyani et al., 1999; Bozdoğan et al., 2000). Some drugs
from the sulfonylurea group have been shown to decrease
myocardial cell damage by increasing fibrinolysis and
decreasing platelet activation and oxidative stress (Thisted
et al., 2006). A combination of glibenclamide with
yohimbine increased the arrhythmia observed in the early
stage of diabetes; this may be due to the ischemic effects
of glibenclamide (Bozdoğan et al., 2000). This suggestion
is supported by clinical findings that higher mortality
following acute myocardial infarction has been observed
more frequently in patients using glibenclamide as an
antidiabetic drug (Thisted et al., 2006). Glibenclamide and
yohimbine have been shown to decrease blood glucose as
well as arrhythmia in myocardial ischemia and reperfusion
in nondiabetic rats (Bozdoğan et al., 2004). However, this
type of synergic effect has not been demonstrated in diabetic
rats. The ineffectiveness of glibenclamide and yohimbine
on blood glucose may be due to the complete damage of

pancreatic beta cells. In this study it was observed that
glibenclamide has a proarrhythmic effect in early diabetes.
However, the effect of glibenclamide in the later stages of
diabetes requires clarification. Yohimbine alone was not
found to be effective for decreasing arrhythmia in diabetic
rats. This ineffectiveness of yohimbine might be due to the
decreased sensitivity of yohimbine in binding the alpha-2
adrenergic receptor (Padayatti and Paulose, 1999).
Body weight and total ventricular weight are
decreased in diabetic rats (Shiomi et al., 2003; Kim et
al., 2012; Haobo et al., 2013). No differences were found
in the blood pressure and heart rate before and during
ischemia and reperfusion in diabetic and nondiabetic
rats. These findings from the present study are consistent
with previous studies (Shiomi et al., 2003; Kim et al.,
2012).
In conclusion, 1 week of diabetes increases the
resistance of the heart against ischemia and reperfusion
injury, thereby decreasing ventricular arrhythmias.
Protection against arrhythmia produced by diabetes did
not change with yohimbine. However, glibenclamide
potentiated these arrhythmias. Further investigation into
the effects of yohimbine and glibenclamide on ischemia
and reperfusion-induced arrhythmia in the late stages of
diabetes can be crucial in order to evaluate the clinical
usage of these drugs.
The effect of glibenclamide alone on ischemia
and reperfusion-induced arrhythmia in diabetic
rats was not researched in this study. That might be
useful for understanding the mechanism of the effect
of glibenclamide on arrhythmias in experimentally
produced myocardial ischemia and reperfusion in
nondiabetic rats. Another limitation of the study is the
number of animals used in each group. The maximum
number in each group was limited to 8 animals.
Increasing the number might be useful to decrease
statistical variation in the different arrhythmic responses
of hearts to ischemia and reperfusion.
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